Follow the Money: Seres Therapeutics, Inc.
Follow the Money highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities.
Seres Therapeutics, Inc. is a U.S. public pharmaceutical company that discovers and develops drugs to treat infectious, metabolic and inflammatory diseases. As reported in the July 2, 2015 issue of the PharmSource Lead Sheet, Seres raised $133 million in the completion of an initial public offering.
- Seres Therapeutics was incorporated in Delaware in 2010 under the name NewCo LS21. In October 2011, the company changed its name to Seres Health, Inc., and in May 2015, the company’s name was changed to Seres Therapeutics, Inc.
- Corporate Headquarters: Cambridge, Massachusetts – approximately 7,461 square feet of office space.
- Facility: Cambridge, Massachusetts – approximately 21,052 of laboratory and office space.
- As of May 13, 2015, Seres had 44 full-time permanent employees, 33 of whom were engaged in research & development.
- Seres plans to use the proceeds to:
- advance the clinical development of SER-109 for the treatment of C. difficile infection, in Phase II development.
- advance the development of SER-262, SER-287 and SER-155 through pre-clinical development and file an investigational new drug application, for one or more of these product candidates.
- fund current and future research & development activities and working capital and other general corporate purposes.
- The company relies on third parties, such as contract research organizations, clinical data management organizations, medical institutions and clinical investigators, to conduct and manage all clinical trials.
- Seres relies on third parties for the manufacture of product candidates for preclinical and clinical testing, as well as for commercial manufacture should any product candidate receive marketing approval.
- The company has no sales, marketing or distribution infrastructure.
|Product Candidate||Indication||Dosage Form||Status||Next Anticipated Step|
|Metabolic Diseases||Type 2 diabetes and metabolic syndrome||Unknown||Discovery||TBA|
|SER-301||Irritable bowel disease||Oral||Discovery||TBA|
|SER-155||Drug resistant bacteria and post-Abx dysbiosis||Oral||Preclinical||Preclinical screening expected to continue until identification of indication|
|SER-262||Primary C. difficile||Oral||Preclinical||Initiation of clinical studies expected in middle of 2016|
|SER-287||Ulcerative colitis||Oral||Preclinical||Initiation of Phase I trial by the end of 2015|
|SER-109||Recurrent C. difficile||Capsule||Phase II||Results of Phase II trial expected in middle of 2016|
|(In $ thousands)||2014||2013|
|General & Administrative Expenditures|
|Total Operating Expenses|
|Seres Therapeutics, Inc.||Key Officers|
|215 First Street||Roger Pomerantz, MD, President & CEO|
|Cambridge, MA 02142, USA||Michele (Shelley) Trucksis, MD, PhD, EVP & CMO|
|Phone: 617-945-9626||David Cook, PhD, CSO & EVP, R&D|
|Web: serestherapeutics.com||Matthew Henn, PhD, SVP & Head, Drug Discovery & Bioinformatics|
|John Aunins, PhD, CTO & EVP, Bioprocess & Manufacturing|